何玉龙 PhD

南京大学教授

学习经历

1999年于英国剑桥大学获博士学位

研究经历

1996.2-1996.9 Visiting Scholar, Department of Obstetrics and Gynaecology, University of Cambridge, UK.

1999.4-2000.11 Research Associate, Department of Pathology, University of Cambridge, UK.

2000.11-2003.8 Postdoctoral Researcher, Molecular / Cancer Biology Laboratory and Ludwig Institute for Cancer Research, Biomedicum Helsinki, University of Helsinki, Finland.

2003.9-2005.5 Scientist, Molecular / Cancer Biology Laboratory and Ludwig Institute for Cancer Research, Biomedicum Helsinki, University of Helsinki, Finland.

2004.12-present Professor, Model Animal Research Center, Nanjing University, China.

研究方向

血管/淋巴管生物学，肿瘤生物学

承担项目

1．负责项目：国家自然资金面上项目（2007-2009），项目批准号：30671038

2．参与项目（技术骨干）：科技部重大科学研究计划（2007-2011）

3．教育部新世纪优秀人才支持计划（2006-2008）

4．南京大学模式动物研究所人才引进启动基金（2005-2007）

研究成果

1） 关于VEGF-A生物活性调控的一个新的机制，即VEGF-A受体FLT-1信使RNA不同剪接在调控VEGF-A生物活性上起重要作用； 2） 抑制VEGF-C受体VEGFR-3的信号船体能抑制肿瘤的淋巴管新生及肿瘤转移到淋巴结； 3） 肿瘤的淋巴管新生源于肿瘤周围组织的淋巴管内皮细胞，而不是骨髓祖细胞； 4） VEGFR-3介导的淋巴管内皮细胞激活在肿瘤细胞进入淋巴管及转移过程中起重要作用。 这些研究结果对于阐述肿瘤转移的分子机制及开发新型抗肿瘤药有重要影响。

论文著作

IF: impact factor (2003)

1.

Holopainen T#, Huang H#, Chen C# （co-first author）, Kim KE, Zhang L, Zhou F, Han W, Li C, Yu J, Wu J, Koh GY, Alitalo K, He Y. Angiopoietin-1 overexpression modulates vascular endothelium to facilitate tumor cell dissemination and establishment. Cancer Res 69:4656-64 (2009). IF: 8.649
2.

Tammela T#, He Y# (co-first author), Lyytikk? J, Jeltsch M, Markkanen J, Pajusola K, Yl?-Herttuala S, Alitalo K. Distinct Architecture of Lymphatic Vessels Induced by Chimeric Vascular Endothelial Growth Factor-C/Vascular Endothelial Growth Factor Heparin-Binding Domain Fusion Proteins. Circ Res 100:1468-75 (2007). IF: 9.408
3.

Wirzenius M, Tammela M, Uutela M, He Y, Odorisio1 T, Zambruno1 G, Nagy JA, Dvorak HF, Yl?-Herttuala S, Shibuya M and Alitalo K. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. J Exp Med 204:1431-40 (2007).. IF: 13.965
4.

Lin J, Lalani AS, Harding TC, Gonzalez M, Wu WW, Luan B, Tu GH, Koprivnikar K, VanRoey MJ, He Y, Alitalo K, Jooss K. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res 65:6901-9 (2005). IF: 8.649
5.

He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, Harding T, Jooss K, Takahashi T, Alitalo K. VEGFR-3 mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res 65:4739-46(2005). IF: 8.649
6.

Bhardwaj S, Roy H, Karpanen T, He Y, Jauhiainen S, Hedman M, Alitalo K, Yla-Herttuala S. Periadventitial angiopoietin-1 gene transfer induces angiogenesis in rabbit carotid arteries. Gene Ther 12:388-94 (2005). IF: 5.293
7.

He Y, Rajantie I, Ilmonen M, Makinen T, Karkkainen MJ, Haiko P, Salven P, Alitalo K. Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis . Cancer Res 64:3737-40 (2004). IF: 8.649
8.

He Y, Karpanen T and Alitalo K. Role of lymphangiogenic factors in lymphatic tumor metastasis. Biochim Biophys Acta 1654:3-12 (2004). IF: 8.395
9.

Uutela M, Wirzenius M, Paavonen K, Rajantie I, He Y, Karpanen T, Lohela M, Wiig H, Salven P, Pajusola K, Eriksson U, Alitalo K. PDGF-D induces macrophage recruitment, increased interstitial pressure and blood vessel maturation during angiogenesis. Blood 104:3198-204 (2004). IF: 10.12
10.

He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, Alitalo K. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 94:785-7 (2002). IF: 13.844
11.

Charnock-Jones DS, He Y and Smith SK. Angiogenesis and Vascular Endothelial Growth Factor (VEGF) in Reproduction. In The New Angiotherapy (eds T-P D Fan & E C Kohn), pp.115-128 (2002). Humana Press.
12.

Smith SK, He Y, Clark DE, Charnock-Jones DS. Angiogenic growth factor expression in placenta. Semin Perinatol 24, 82-86 (2000). IF: 1.413
13.

He Y, Smith SK, Day KA, Clark D, Licence DR, Charnock-Jones DS. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. Mol Endocrinol 13:537-545 (1999). IF: 5.708
14.

Clark DE, Smith SK, He Y, Day KA, Licence DR, Corps AN, and Charnock-Jones DS. A vascular endothelial growth factor antagonist is produced by the placenta and released into the maternal circulation. Biol Reprod 59:1540-1548 (1998). IF: 3.646

专利

Alitalo K, He Y, Tammela T. Heparin binding VEGFR-3 ligands (United States Patent Application, published on February 10, 2005，20050032697).
Alitalo K, Saaristo A, Karkkainen M, Tammela T, Asko-Seljavaara S, Yla-Herttuala S, He Y. Use of VEGF-C or VEGF-D in reconstructive surgery (United States Patent Application, published on February 24, 2005，20050043235)Exception in thread "main" java.lang.NullPointerException
at txtfilter.addbold.main(addbold.java:34)

学术职务

教授，博士生导师

Active member, American Association for Cancer Research (AACR, Jun. 2004--present)

通联信息

办公室：58641512

实验室：58641522

电子邮件: yhe20005@yahoo.com

yulong.he@nicemice.cn